CAPhO Upcoming Webinar: Managing Adverse Events and Drug-Drug Interactions Associated with CDK4/6i in Patients with HR+/HER2- Metastatic Breast Cancer
Sponsored by Pfizer Oncology Canada
Thursday, June 8, 2023 at 17:00 PDT, 18:00 MDT, 19:00 CDT, 20:00 EDT, 21:00 ADT, 21:30 NDT
In HR+/HER2- metastatic breast cancer (mBC), CDK4/6 inhibitors (CDK4/6i) are standard of care in the first-line setting. The CDK4/6i have different safety and tolerability profiles compared to each other and the endocrine and cytotoxic therapies that were traditionally used in this population. It is an interactive case-based webinar developed by Pfizer Oncology Canada. The webinar will build your understanding of the adverse events and drug interactions observed with this class of drug and apply this clinical knowledge to the management of your patients with mBC treated with CDK4/6i.
By the end of the webinar, participants will be able to:
- Discuss the common adverse events (AEs) that are associated with CDK4/6 inhibitor (CDK4/6i) treatment in patients with HR+/HER2- metastatic breast cancer (mBC), including their incidence, severity, and management strategies;
- Identify key drug-drug interactions (DDIs) with the different CDK4/6i; and
- Apply this knowledge of AE and DDI monitoring and management to relevant patient cases.